GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Betty Lawrence
Angiochem Inc
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mcgill Univ.
Montreal, Quebec, Canada
- Univ. of California San Diego
La Jolla, California, United States
- Univ. Coloardo at Denver
Aurora, Colorado, United States
- H. Lee Moffitt Cancer Center
Tampa, Florida, United States
- Northwestern Univ.
Chicago, Illinois, United States
- Ingalls Memorial Hospital
Harvey, Illinois, United States
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
- Karmanos Cancer Institute
Detroit, Michigan, United States
- Univ. of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
- Tennessee Oncology
Nashville, Tennessee, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Nov 2011
- Primary completion
- 31 Jan 2013
- Completion
- 28 Feb 2013
- Last update posted
- 22 Jan 2019
- Registered enrollment
- 16
- Registry id
- NCT01497665
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.